BRCA 1 & 2 COMPREHENSIVE (MLPA & Germline)
MRP - ₹ 30,000
What is a BRCA 1 & 2 COMPREHENSIVE (MLPA & Germline)?
The BRCA1 & BRCA2 Comprehensive (MLPA & Germline) test is a genetic test designed to detect mutations in the BRCA1 and BRCA2 genes, which are strongly associated with hereditary breast and ovarian cancers. Using techniques like MLPA (Multiplex Ligation-dependent Probe Amplification) and germline mutation analysis, this test identifies both large gene rearrangements and inherited mutations. It is performed to assess cancer risk, guide preventive strategies, and support personalized treatment decisions for individuals with a family history of breast or ovarian cancer.
Additional Information
| Also known as/ Other names: | BRCA1 and BRCA2 Comprehensive Panel, BRCA Germline Mutation Analysis, BRCA1/2 MLPA and Sequencing Test, Comprehensive BRCA Genetic Testing |
| Parameters: | 1 |
| Recommended for: | M/F/Others |
| Sample Type: | Blood |
| Patient Preparation: | Minimum gap from Chemotherapy should be 2 weeks |
| Reports: | 4-6 weeks |
FAQs
It helps assess inherited cancer risk, guide preventive strategies, and support personalized treatment decisions.
Individuals with a family history of breast, ovarian, or related cancers are recommended for testing.
A positive result indicates a BRCA mutation, increasing cancer risk and guiding preventive or therapeutic measures.
It suggests no detectable BRCA mutations, though other genetic factors may still influence cancer risk.
No, medications do not interfere with genetic mutation detection.
Without testing, hereditary cancer risk may remain unknown, delaying preventive care.
It is usually done once, as genetic mutations do not change over time.